

01-02-02

A

10/26/01

Docket Number 4-31440A/C1/HO29

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10EL 751039565 US
Express Mail Label NumberOctober 26, 2001
Date of DepositAddress to: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231**UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET**

Transmitted herewith for filing under 37 CFR §1.53(b)(1) is a **continuation** of prior Application No. 09/575,302, filed May 19, 2000.

JC857 U.S. PRO
10/032626
10/26/01



Applicant (or identifier): JARAI ET AL.

Title: NOVEL GENE

Enclosed are:

1. Specification (Including Claims and Abstract) - 25 pages
2. Drawings - sheets
3. Declaration and Power of Attorney
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (signed or with indication that original was signed)
 - i. Deletion of Inventors
Signed statement attached deleting inventor(s) named in the prior application
4. Incorporation By Reference
The entire disclosure of the prior application, from which a copy of the Declaration and Power of Attorney is supplied under Box 3b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
5. Microfiche Computer Program (appendix)
6. Nucleotide and/or Amino Acid Sequence Submission
 - Computer Readable Copy
 - Paper Copy
 - Statement Verifying Identity of Above Copies
7. Preliminary Amendment
8. Assignment Papers (Cover Sheet & Document(s))
9. English Translation of
10. Information Disclosure Statement with form PTO-1449
11. Certified Copy of Priority Document(s)
12. Return Receipt Postcard
13. Other: Application Data Sheet

The right to elect an invention or species that is different from that elected in parent Application No. in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent application is hereby reserved.

Filing fee calculation:

Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
 Before calculating the filing fee, please cancel claims .

Basic Filing Fee							\$ 740
Multiple Dependent Claim Fee (\$ 280)							\$
Foreign Language Surcharge (\$ 900)							\$
	For	Number Filed		Number Extra		Rate	
Extra Claims	Total Claims	9	-20	0	x \$ 18	=	\$
	Independent Claims	2	-3	0	x \$ 84	=	\$
TOTAL FILING FEE							\$ 740

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of **\$740**. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie
 Novartis Corporation
 Patent and Trademark Dept.
 564 Morris Avenue
 Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (908) 522-6955.

Respectfully submitted,

David E. Wildman
 Attorney for Applicants
 Reg. No. 40,226
 Tel. No. (908) 522-6946

Date: October 26, 2001

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 751039565 US
Express Mail Label Number

October 26, 2001
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

JARAI ET AL.

APPLICATION NO: Not Yet Assigned

FILED: OCTOBER 25, 2001

FOR: NOVEL GENE

Assistant Commissioner for Patents
Washington, D.C. 20231

**SUBMISSION OF SEQUENCE LISTING
INCLUDING STATEMENT OF VERIFICATION**

Sir:

Applicants hereby provide a paper copy of the Sequence Listing. Applicants respectfully request that the computer readable form of the Sequence Listing present in prior related application Ser. No. 09/575,302, filed May 19, 2000, be used in the present application pursuant to 37 CFR § 1.821(e). The undersigned states that the paper copy submitted herewith is identical to the computer readable form of the Sequence Listing submitted in parent application Ser. No. 09/575,302, filed May 19, 2000.

Respectfully submitted,



David E. Wildman
Attorney for Applicants
Reg. No. 40,226

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6946
Date: October 26, 2001